Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics

Show simple item record

dc.contributor.author Kleerebezem, Michiel
dc.contributor.author Binda, Sylvie
dc.contributor.author Bron, Peter A.
dc.contributor.author Gross, Gabriele
dc.contributor.author Hill, Colin
dc.contributor.author van Hylckama Vlieg, Johan E. T.
dc.contributor.author Lebeer, Sarah
dc.contributor.author Satokari, Reetta
dc.contributor.author Ouwehand, Arthur C.
dc.date.accessioned 2019-10-01T05:11:39Z
dc.date.available 2019-10-01T05:11:39Z
dc.date.issued 2018-10-05
dc.identifier.citation Kleerebezem, M., Binda, S., Bron, P.A., Gross, G., Hill, C., van Hylckama Vlieg, J.E., Lebeer, S., Satokari, R. and Ouwehand, A.C., 2019. Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics. Current opinion in biotechnology, 56, (5pp). DOI:10.1016/j.copbio.2018.09.007 en
dc.identifier.volume 56 en
dc.identifier.startpage 55 en
dc.identifier.endpage 60 en
dc.identifier.issn 0958-1669
dc.identifier.uri http://hdl.handle.net/10468/8645
dc.identifier.doi 10.1016/j.copbio.2018.09.007 en
dc.description.abstract The different levels of knowledge described in a translational pipeline (the connection of molecular mechanisms with pre-clinical physiological and human health effects) are not complete for many probiotics. At present, we are not in a position to fully understand the mechanistic basis of many well established probiotic health benefits which, in turn, limits our ability to use mechanisms to predict which probiotics are likely to be effective in any given population. Here we suggest that this concept of a translation pipeline connecting mechanistic insights to probiotic efficacy can support the selection and production of improved probiotic products. Such a conceptual pipeline would also provide a framework for the design of clinical trials to convincingly demonstrate the benefit of probiotics to human health in well-defined subpopulations. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Elsevier Ltd en
dc.relation.uri https://www.sciencedirect.com/science/article/pii/S0958166918300910
dc.rights © 2018 The Authors. Published by Elsevier Ltd en
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/ en
dc.subject Probiotics en
dc.subject Human health effects en
dc.subject Translation pipeline en
dc.title Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Colin Hill, School of Microbiology and APC Microbiome Ireland, University College Cork, Cork, Ireland. +353-21-490-3000 Email: c.hill@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder ILSI Europe Probiotics Task Force en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Current Opinion in Biotechnology en
dc.internal.IRISemailaddress c.hill@ucc.ie en
dc.identifier.eissn 1879-0429


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2018 The Authors. Published by Elsevier Ltd Except where otherwise noted, this item's license is described as © 2018 The Authors. Published by Elsevier Ltd
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement